KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $6.6 billion.

  • Vertex Pharmaceuticals' Cash & Current Investments rose 804.79% to $6.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $6.6 billion, marking a year-over-year increase of 804.79%. This contributed to the annual value of $6.6 billion for FY2025, which is 804.79% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Cash & Current Investments of $6.6 billion as of Q4 2025, which was up 804.79% from $6.3 billion recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Cash & Current Investments ranged from a high of $11.9 billion in Q3 2023 and a low of $5.8 billion during Q2 2024
  • Over the past 5 years, Vertex Pharmaceuticals' median Cash & Current Investments value was $7.2 billion (recorded in 2021), while the average stood at $8.3 billion.
  • In the last 5 years, Vertex Pharmaceuticals' Cash & Current Investments skyrocketed by 6523.35% in 2021 and then plummeted by 4842.16% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Cash & Current Investments (Quarter) stood at $7.5 billion in 2021, then skyrocketed by 43.24% to $10.8 billion in 2022, then rose by 4.08% to $11.2 billion in 2023, then plummeted by 45.48% to $6.1 billion in 2024, then increased by 8.05% to $6.6 billion in 2025.
  • Its last three reported values are $6.6 billion in Q4 2025, $6.3 billion for Q3 2025, and $6.4 billion during Q2 2025.